Year |
Citation |
Score |
2022 |
Barnard DL, Belnap DM, Azadi P, Heiss C, Snyder DS, Bock SC, Konowalchuk TW. Examining the interactions of Galahad™ compound with viruses to develop a novel inactivated influenza A virus vaccine. Heliyon. 8: e09887. PMID 35821966 DOI: 10.1016/j.heliyon.2022.e09887 |
0.356 |
|
2020 |
Warfield K, Alonzi DS, Hill J, Caputo A, Roversi P, Kiappes JL, Sheets N, Duchars M, Dwek R, Biggins J, Barnard DL, Shresta S, Treston A, Zitzmann N. Targeting ER α-glucosidase I with a single-dose iminosugar treatment protects against lethal influenza and dengue virus infections. Journal of Medicinal Chemistry. PMID 32227946 DOI: 10.1021/Acs.Jmedchem.0C00067 |
0.48 |
|
2019 |
Warfield KL, Schaaf KR, DeWald LE, Spurgers KB, Wang W, Stavale E, Mendenhall M, Shilts MH, Stockwell TB, Barnard DL, Ramstedt U, Das SR. Lack of selective resistance of influenza A virus in presence of host-targeted antiviral, UV-4B. Scientific Reports. 9: 7484. PMID 31097731 DOI: 10.1038/S41598-019-43030-Y |
0.489 |
|
2018 |
Kumaki Y, Woolcott JD, Roth JP, Mclean TZ, Smee DF, Barnard DL, Valiaeva N, Beadle JR, Hostetler KY. Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro. Antiviral Research. PMID 30096340 DOI: 10.1016/J.Antiviral.2018.08.004 |
0.766 |
|
2017 |
Basu A, Komazin-Meredith G, McCarthy C, Antanasijevic A, Cardinale SC, Mishra RK, Barnard DL, Caffrey M, Rong L, Bowlin TL. Molecular Mechanism Underlying the Action of the Influenza A Virus Fusion Inhibitor MBX2546. Acs Infectious Diseases. PMID 28301927 DOI: 10.1021/Acsinfecdis.6B00194 |
0.447 |
|
2016 |
Kumaki Y, Salazar AM, Wandersee MK, Barnard DL. Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol(®) (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model. Antiviral Research. PMID 27956136 DOI: 10.1016/J.Antiviral.2016.12.007 |
0.47 |
|
2016 |
Smee DF, Barnard DL, Jones SM. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Research. PMID 27771390 DOI: 10.1016/J.Antiviral.2016.10.009 |
0.52 |
|
2016 |
Vollmer AH, Gebre MS, Barnard DL. Serum amyloid A (SAA) is an early biomarker of influenza virus disease in BALB/c, C57BL/2, Swiss-Webster, and DBA.2 mice. Antiviral Research. PMID 27523492 DOI: 10.1016/J.Antiviral.2016.08.011 |
0.504 |
|
2016 |
McPherson C, Chubet R, Holtz K, Honda-Okubo Y, Barnard D, Cox M, Petrovsky N. Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant. Methods in Molecular Biology (Clifton, N.J.). 1403: 269-84. PMID 27076136 DOI: 10.1007/978-1-4939-3387-7_14 |
0.336 |
|
2016 |
Warfield KL, Barnard DL, Enterlein SG, Smee DF, Khaliq M, Sampath A, Callahan MV, Ramstedt U, Day CW. The Iminosugar UV-4 is a Broad Inhibitor of Influenza A and B Viruses ex Vivo and in Mice. Viruses. 8. PMID 27072420 DOI: 10.3390/V8030071 |
0.452 |
|
2015 |
Tharakaraman K, Subramanian V, Viswanathan K, Sloan S, Yen HL, Barnard DL, Leung YH, Szretter KJ, Koch TJ, Delaney JC, Babcock GJ, Wogan GN, Sasisekharan R, Shriver Z. A broadly neutralizing human monoclonal antibody is effective against H7N9. Proceedings of the National Academy of Sciences of the United States of America. 112: 10890-5. PMID 26283346 DOI: 10.1073/Pnas.1502374112 |
0.442 |
|
2015 |
Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Research. 116: 76-84. PMID 25666761 DOI: 10.1016/J.Antiviral.2015.01.011 |
0.517 |
|
2015 |
Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. Journal of Virology. 89: 2995-3007. PMID 25520500 DOI: 10.1128/Jvi.02980-14 |
0.322 |
|
2014 |
Tarbet EB, Vollmer AH, Hurst BL, Barnard DL, Furuta Y, Smee DF. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. Archives of Virology. 159: 1279-91. PMID 24311151 DOI: 10.1007/S00705-013-1922-1 |
0.492 |
|
2014 |
Basu A, Antanasijevic A, Wang M, Li B, Mills DM, Ames JA, Nash PJ, Williams JD, Peet NP, Moir DT, Prichard MN, Keith KA, Barnard DL, Caffrey M, Rong L, et al. New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion. Journal of Virology. 88: 1447-60. PMID 24198411 DOI: 10.1128/Jvi.01225-13 |
0.515 |
|
2013 |
Smee DF, Tarbet EB, Furuta Y, Morrey JD, Barnard DL. Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virology. 8: 1085-1094. PMID 24563658 DOI: 10.2217/Fvl.13.98 |
0.539 |
|
2013 |
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research. 100: 446-54. PMID 24084488 DOI: 10.1016/J.Antiviral.2013.09.015 |
0.503 |
|
2013 |
Smee DF, Barnard DL. Methods for evaluation of antiviral efficacy against influenza virus infections in animal models. Methods in Molecular Biology (Clifton, N.J.). 1030: 407-25. PMID 23821285 DOI: 10.1007/978-1-62703-484-5_31 |
0.537 |
|
2013 |
Roth JP, Li JK, Morrey JD, Barnard DL, Vollmer AH. Deletion of the D domain of the human parainfluenza virus type 3 (HPIV3) PD protein results in decreased viral RNA synthesis and beta interferon (IFN-β) expression. Virus Genes. 47: 10-9. PMID 23686695 DOI: 10.1007/S11262-013-0919-X |
0.746 |
|
2013 |
Kim MK, Yoon H, Barnard DL, Chong Y. Design, synthesis and antiviral activity of 2-(3-amino-4-piperazinylphenyl)chromone derivatives. Chemical & Pharmaceutical Bulletin. 61: 486-8. PMID 23546009 DOI: 10.1248/Cpb.C12-01050 |
0.427 |
|
2013 |
Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Barnard DL, Bates JT, Crowe JE, Piedra PA, Gilbert BE. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model Mabs. 5: 263-269. PMID 23396091 DOI: 10.4161/Mabs.23281 |
0.378 |
|
2013 |
Kesel AJ, Weiss HC, Schönleber A, Day CW, Barnard DL, Detorio MA, Schinazi RF. Antiviral agents derived from novel 1-adamantyl singlet nitrenes. Antiviral Chemistry & Chemotherapy. 23: 113-28. PMID 23234699 DOI: 10.3851/Imp2485 |
0.511 |
|
2012 |
Kumaki Y, Morrey JD, Barnard DL. Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. Future Virology. 7: 801-818. PMID 23420457 DOI: 10.2217/Fvl.12.71 |
0.527 |
|
2012 |
Nguyen JT, Smee DF, Barnard DL, Julander JG, Gross M, de Jong MD, Went GT. Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. Plos One. 7: e31006. PMID 22292088 DOI: 10.1371/Journal.Pone.0031006 |
0.464 |
|
2011 |
Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Research. 92: 329-40. PMID 21925541 DOI: 10.1016/J.Antiviral.2011.09.001 |
0.554 |
|
2011 |
Julander JG, Hagloch J, Latimer S, Motter N, Dagley A, Barnard DL, Smee DF, Morrey JD. Use of plethysmography in assessing the efficacy of antivirals in a mouse model of pandemic influenza A virus. Antiviral Research. 92: 228-36. PMID 21867731 DOI: 10.1016/J.Antiviral.2011.08.011 |
0.469 |
|
2011 |
Barnard DL, Kumaki Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virology. 6: 615-631. PMID 21765859 DOI: 10.2217/Fvl.11.33 |
0.468 |
|
2011 |
Liu YV, Massare MJ, Barnard DL, Kort T, Nathan M, Wang L, Smith G. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Vaccine. 29: 6606-13. PMID 21762752 DOI: 10.1016/J.Vaccine.2011.06.111 |
0.424 |
|
2011 |
Barnard D, Li JK. Commentary on Immune System Associated Diseases Caused by Viruses: The Role of EBV. Frontiers in Microbiology. 2: 28. PMID 21687420 DOI: 10.3389/Fmicb.2011.00028 |
0.407 |
|
2011 |
Kumaki Y, Wandersee MK, Smith AJ, Zhou Y, Simmons G, Nelson NM, Bailey KW, Vest ZG, Li JK, Chan PK, Smee DF, Barnard DL. Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin. Antiviral Research. 90: 22-32. PMID 21338626 DOI: 10.1016/J.Antiviral.2011.02.003 |
0.556 |
|
2011 |
Kumaki Y, Ennis J, Rahbar R, Turner JD, Wandersee MK, Smith AJ, Bailey KW, Vest ZG, Madsen JR, Li JK, Barnard DL. Single-dose intranasal administration with mDEF201 (adenovirus vectored mouse interferon-alpha) confers protection from mortality in a lethal SARS-CoV BALB/c mouse model. Antiviral Research. 89: 75-82. PMID 21093489 DOI: 10.1016/J.Antiviral.2010.11.007 |
0.427 |
|
2010 |
Yang CW, Lee YZ, Kang IJ, Barnard DL, Jan JT, Lin D, Huang CW, Yeh TK, Chao YS, Lee SJ. Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus. Antiviral Research. 88: 160-8. PMID 20727913 DOI: 10.1016/J.Antiviral.2010.08.009 |
0.474 |
|
2010 |
Roth JP, Li JK, Barnard DL. Human parainfluenza virus type 3 (HPIV-3): construction and rescue of an infectious, recombinant virus expressing the enhanced green fluorescent protein (EGFP). Current Protocols in Microbiology. Unit 15F.1. PMID 20440682 DOI: 10.1002/9780471729259.Mc15F01S17 |
0.774 |
|
2010 |
Kumaki Y, Day CW, Bailey KW, Wandersee MK, Wong MH, Madsen JR, Madsen JS, Nelson NM, Hoopes JD, Woolcott JD, McLean TZ, Blatt LM, Salazar AM, Smee DF, Barnard DL. Induction of interferon-gamma-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice. Antiviral Chemistry & Chemotherapy. 20: 169-77. PMID 20231782 DOI: 10.3851/Imp1477 |
0.442 |
|
2010 |
Rao JR, Jha AK, Rawal RK, Sharon A, Day CW, Barnard DL, Smee DF, Chu CK. (-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu). Bioorganic & Medicinal Chemistry Letters. 20: 2601-4. PMID 20231094 DOI: 10.1016/J.Bmcl.2010.02.074 |
0.482 |
|
2010 |
O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL, McCray PB. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. Journal of Virology. 84: 2511-21. PMID 20032190 DOI: 10.1128/Jvi.02322-09 |
0.497 |
|
2010 |
Silvers L, Barnard D, Knowlton F, Inglis B, Labudovic A, Holland MK, Janssens PA, van Leeuwen BH, Kerr PJ. Host-specificity of myxoma virus: Pathogenesis of South American and North American strains of myxoma virus in two North American lagomorph species. Veterinary Microbiology. 141: 289-300. PMID 19836172 DOI: 10.1016/J.Vetmic.2009.09.031 |
0.461 |
|
2010 |
Tarbet B, Hurst B, Barnard D, Babu Y, Furuta Y, Smee D. Antiviral Drug Efficacy Evaluation Against Pandemic Influenza a (H1N1) Viruses in MDCK Cells Antiviral Research. 86: A48. DOI: 10.1016/J.Antiviral.2010.02.414 |
0.431 |
|
2010 |
Gowen B, Barnard D, Wong M, Larson D, Wu J, Ennis J, Morrey J, Turner J. Single-dose Intranasal Delivery with DEF201 (Adenovirus Vectored Mouse Interferon-α) Protects Against Phlebovirus and Sars Coronavirus Challenge Antiviral Research. 86: A34. DOI: 10.1016/J.Antiviral.2010.02.376 |
0.31 |
|
2010 |
Barnard D, Furuta Y, Klummp K, Smee D, Morrey J, Tarbet B. In Vitro and In Vivo Efficacy of Combinational Therapy with Favipiravir (T-705) and Oseltamivir Against Influenza A/CA/04/09 Pandemic H1N1 Virus Antiviral Research. 86: A26. DOI: 10.1016/J.Antiviral.2010.02.351 |
0.434 |
|
2010 |
Gross M, Le M, Smee D, Barnard D, Patick A, Nguyen J. The Triple Combination Antiviral Drug (TCAD) Regimen of Amantadine, Ribavirin, and Oseltamivir is Highly Efficacious Against Susceptible and Resistant Influenza Virus Strains in Mouse Treatment Models Antiviral Research. 86: A25-A26. DOI: 10.1016/J.Antiviral.2010.02.350 |
0.433 |
|
2009 |
Day CW, Baric R, Cai SX, Frieman M, Kumaki Y, Morrey JD, Smee DF, Barnard DL. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 395: 210-22. PMID 19853271 DOI: 10.1016/J.Virol.2009.09.023 |
0.367 |
|
2009 |
Wiley JA, Richert LE, Swain SD, Harmsen A, Barnard DL, Randall TD, Jutila M, Douglas T, Broomell C, Young M, Harmsen A. Inducible bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. Plos One. 4: e7142. PMID 19774076 DOI: 10.1371/Journal.Pone.0007142 |
0.397 |
|
2009 |
Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Research. 82: 95-102. PMID 19428599 DOI: 10.1016/J.Antiviral.2009.02.198 |
0.551 |
|
2009 |
Roth JP, Li JK, Smee DF, Morrey JD, Barnard DL. A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays. Antiviral Research. 82: 12-21. PMID 19189850 DOI: 10.1016/J.Antiviral.2009.01.001 |
0.771 |
|
2009 |
Barnard DL. Animal models for the study of influenza pathogenesis and therapy. Antiviral Research. 82: A110-22. PMID 19176218 DOI: 10.1016/J.Antiviral.2008.12.014 |
0.505 |
|
2009 |
Roth J, McLean T, Valiaeva N, Beadle J, Hostetler K, Barnard D. Antiviral Activity of Octadecyloxypropyl Esters of 3-Hydroxy-2-(Phosphonomethoxy)Propyl Nucleosides Against Adenovirus In Vitro Antiviral Research. 82: A41-A42. DOI: 10.1016/J.Antiviral.2009.02.088 |
0.737 |
|
2009 |
Kumaki Y, Day CW, Wandersee MK, Madsen JR, Woolcott JD, Hoopes JD, Bailey KW, Wong M, Smee DF, Morrey JD, Barnard DL. Induction of Interferon Gamma Inducible Protein 10 by SARS-CoV Infection, Interferon Alfacon 1 and Interferon Inducer in Human Bronchial Epithelial Calu-3 Cells and BALB/c Mice Antiviral Research. 82: A34. DOI: 10.1016/J.Antiviral.2009.02.064 |
0.386 |
|
2009 |
Barnard D, Wiley J, Wandersee M, Kumaki Y, Young M, Douglas T, Harmsen A. Prophylactic Efficacy of Intranasally Administered HSP Nanoparticles for Treating a Lethal SARS-CoV Infection in BALB/c Mice Antiviral Research. 82: A32. DOI: 10.1016/J.Antiviral.2009.02.059 |
0.327 |
|
2008 |
Barnard DL. Coronaviruses: Molecular and Cellular Biology. Future Virology. 3: 119-123. PMID 32218805 DOI: 10.2217/17460794.3.2.119 |
0.344 |
|
2008 |
Smee DF, Humphreys DE, Hurst BL, Barnard DL. Antiviral activities and phosphorylation of 5-halo-2'-deoxyuridines and N-methanocarbathymidine in cells infected with vaccinia virus. Antiviral Chemistry & Chemotherapy. 19: 15-24. PMID 18610554 DOI: 10.1177/095632020801900103 |
0.394 |
|
2008 |
Subramanian GM, Moore PA, Gowen BB, Olsen AL, Barnard DL, Paragas J, Hogan RJ, Sidwell RW. Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus. Chemotherapy. 54: 176-80. PMID 18560223 DOI: 10.1159/000140361 |
0.343 |
|
2008 |
Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Jung KH, Li JK, Chan PK, Sidwell RW. Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections? Lack of efficacy of promazine on SARS-CoV replication in a mouse model. Antiviral Research. 79: 105-13. PMID 18423639 DOI: 10.1016/J.Antiviral.2007.12.005 |
0.525 |
|
2008 |
Kumaki Y, Day CW, Wandersee MK, Schow BP, Madsen JS, Grant D, Roth JP, Smee DF, Blatt LM, Barnard DL. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochemical and Biophysical Research Communications. 371: 110-3. PMID 18406349 DOI: 10.1016/J.Bbrc.2008.04.006 |
0.76 |
|
2008 |
Chu C, Rao J, Day C, Barnard D, Smee D. Antiviral Activity of (−)-d-Carbocyclic Cytosine (Carbodine) Against Avian Influenza Virus (H5N1) Antiviral Research. 78: A55. DOI: 10.1016/J.ANTIVIRAL.2008.01.114 |
0.375 |
|
2008 |
Barnard D, Day C, Wandersee M, Kumaki Y, Salazar A. Evaluation of Interferon Inducers, Ribavirin and Mouse Hyperimmune Serum in a Pathogenesis/Lethal Mouse Model Using a Mouse-adapted SARS-CoV Antiviral Research. 78: A20. DOI: 10.1016/J.Antiviral.2008.01.025 |
0.311 |
|
2007 |
Selvam P, Vijayalakshimi P, Smee DF, Gowen BB, Julander JG, Day CW, Barnard DL. Novel 3-sulphonamido-quinazolin-4(3H)-one derivatives: microwave-assisted synthesis and evaluation of antiviral activities against respiratory and biodefense viruses. Antiviral Chemistry & Chemotherapy. 18: 301-5. PMID 18046963 DOI: 10.1177/095632020701800506 |
0.506 |
|
2007 |
Hu MC, Jones T, Kenney RT, Barnard DL, Burt DS, Lowell GH. Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice. Vaccine. 25: 6334-40. PMID 17640780 DOI: 10.1016/J.Vaccine.2007.06.017 |
0.34 |
|
2007 |
Barnard DL, Wong MH, Bailey K, Day CW, Sidwell RW, Hickok SS, Hall TJ. Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice. Antiviral Chemistry & Chemotherapy. 18: 125-32. PMID 17626596 DOI: 10.1177/095632020701800302 |
0.542 |
|
2007 |
Borkow G, Sidwell RW, Smee DF, Barnard DL, Morrey JD, Lara-Villegas HH, Shemer-Avni Y, Gabbay J. Neutralizing viruses in suspensions by copper oxide-based filters. Antimicrobial Agents and Chemotherapy. 51: 2605-7. PMID 17470650 DOI: 10.1128/Aac.00125-07 |
0.305 |
|
2007 |
Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrobial Agents and Chemotherapy. 51: 845-51. PMID 17194832 DOI: 10.1128/Aac.01051-06 |
0.54 |
|
2007 |
SELVAM P, SMEE D, GOWEN B, DAY C, BARNARD D, MORREY J. Design, Synthesis, Antiviral Activity and Cytotoxicity of Novel Sulphonamide Derivatives Antiviral Research. 74: A81-A81. DOI: 10.1016/J.Antiviral.2007.01.139 |
0.342 |
|
2007 |
BARNARD D, HU M, JONES T, KENNEY R, BURT D, LOWELL G. Intranasal Protollin Formulated Recombinant SARS-CoV S Protein Elicits Respiratory and Serum Neutralizing Antibodies Antiviral Research. 74: A45-A45. DOI: 10.1016/J.Antiviral.2007.01.051 |
0.344 |
|
2006 |
Chu CK, Gadthula S, Chen X, Choo H, Olgen S, Barnard DL, Sidwell RW. Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-coV). Antiviral Chemistry & Chemotherapy. 17: 285-9. PMID 17176633 DOI: 10.1177/095632020601700506 |
0.409 |
|
2006 |
Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Chan PK, Sidwell RW. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antiviral Chemistry & Chemotherapy. 17: 275-84. PMID 17176632 DOI: 10.1177/095632020601700505 |
0.527 |
|
2006 |
Sidwell RW, Barnard DL. Respiratory syncytial virus infections: recent prospects for control. Antiviral Research. 71: 379-90. PMID 16806515 DOI: 10.1016/J.Antiviral.2006.05.014 |
0.423 |
|
2006 |
Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, Winslow S, Hoopes J, Li JK, Lee J, Carson DA, Cottam HB, Sidwell RW. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Research. 71: 53-63. PMID 16621037 DOI: 10.1016/J.Antiviral.2006.03.001 |
0.502 |
|
2006 |
Barnard DL. Current status of anti-picornavirus therapies. Current Pharmaceutical Design. 12: 1379-90. PMID 16611122 DOI: 10.2174/138161206776361129 |
0.419 |
|
2005 |
Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Research. 68: 10-7. PMID 16087250 DOI: 10.1016/J.Antiviral.2005.06.003 |
0.532 |
|
2005 |
Gowen BB, Barnard DL, Smee DF, Wong MH, Pace AM, Jung KH, Winslow SG, Bailey KW, Blatt LM, Sidwell RW. Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrobial Agents and Chemotherapy. 49: 2378-86. PMID 15917537 DOI: 10.1128/Aac.49.6.2378-2386.2005 |
0.479 |
|
2004 |
Barnard DL. Inhibitors of measles virus. Antiviral Chemistry & Chemotherapy. 15: 111-9. PMID 15266893 DOI: 10.1177/095632020401500301 |
0.423 |
|
2004 |
Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrobial Agents and Chemotherapy. 48: 1766-72. PMID 15105133 DOI: 10.1128/Aac.48.5.1766-1772.2004 |
0.415 |
|
2004 |
Barnard DL, Hubbard VD, Burton J, Smee DF, Morrey JD, Otto MJ, Sidwell RW. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antiviral Chemistry & Chemotherapy. 15: 15-22. PMID 15074711 DOI: 10.1177/095632020401500102 |
0.424 |
|
2003 |
Watson KG, Brown RN, Cameron R, Chalmers DK, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell DB, Reece PA, Ryan J, Stanislawski PC, Tucker SP, Wu WY, Barnard DL, et al. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. Journal of Medicinal Chemistry. 46: 3181-4. PMID 12852746 DOI: 10.1021/Jm0202876 |
0.341 |
|
2002 |
Zhang N, Chen HM, Sood R, Kalicharran K, Fattom AI, Naso RB, Barnard DL, Sidwell RW, Hosmane RS. in vitro inhibition of the measles virus by novel ring-expanded ('fat') nucleoside analogues containing the imidazo[4,5-e]diazepine ring system. Bioorganic & Medicinal Chemistry Letters. 12: 3391-4. PMID 12419368 DOI: 10.1016/S0960-894X(02)00762-X |
0.417 |
|
2002 |
Smee DF, Morrison AC, Barnard DL, Sidwell RW. Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. Journal of Virological Methods. 106: 71-9. PMID 12367731 DOI: 10.1016/S0166-0934(02)00137-4 |
0.524 |
|
2002 |
Barnard DL, Xu Ze, Stowell VD, Yuan H, Smee DF, Samy R, Sidwell RW, Nielsen MK, Sun L, Cao H, Li A, Quint C, Deignan J, Crabb J, Flavin MT. Coumarins and pyranocoumarins, potential novel pharmacophores for inhibition of measles virus replication. Antiviral Chemistry & Chemotherapy. 13: 39-59. PMID 12180648 DOI: 10.1177/095632020201300104 |
0.432 |
|
2001 |
Sidwell RW, Wong MH, Bailey KW, Barnard DL, Jackson MK, Smee DF. Utilization of alpha-1-acid glycoprotein levels in the serum as a parameter for in vivo assay of influenza virus inhibitors Antiviral Chemistry and Chemotherapy. 12: 359-365. PMID 12018681 DOI: 10.1177/095632020101200606 |
0.525 |
|
2001 |
Barnard DL, Stowell VD, Seley KL, Hegde VR, Das SR, Rajappan VP, Schneller SW, Smee DF, Sidwell RW. Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues. Antiviral Chemistry & Chemotherapy. 12: 241-50. PMID 11771733 DOI: 10.1177/095632020101200405 |
0.494 |
|
2001 |
Baniecki ML, McGrath WJ, McWhirter SM, Li C, Toledo DL, Pellicena P, Barnard DL, Thorn KS, Mangel WF. Interaction of the human adenovirus proteinase with its 11-amino acid cofactor pVIc. Biochemistry. 40: 12349-56. PMID 11591154 DOI: 10.1021/Bi0109008 |
0.312 |
|
2001 |
Sidwell RW, Smee DF, Huffman JH, Barnard DL, Morrey JD, Bailey KW, Feng WC, Babu YS, Bush K. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201 Antiviral Research. 51: 179-187. PMID 11448729 DOI: 10.1016/S0166-3542(01)00149-8 |
0.539 |
|
2001 |
Mangel WF, McGrath WJ, Brown MT, Baniecki ML, Barnard DL, Pang YP. A new form of antiviral combination therapy predicted to prevent resistance from arising, and a model system to test it. Current Medicinal Chemistry. 8: 933-9. PMID 11375760 DOI: 10.2174/0929867013372742 |
0.388 |
|
2001 |
Sidwell RW, Smee DF, Huffman JH, Barnard DL, Bailey KW, Morrey JD, Babu YS. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201 Antimicrobial Agents and Chemotherapy. 45: 749-757. PMID 11181355 DOI: 10.1128/Aac.45.3.749-757.2001 |
0.531 |
|
2001 |
Smee DF, Huffman JH, Morrison AC, Barnard DL, Sidwell RW. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrobial Agents and Chemotherapy. 45: 743-8. PMID 11181354 DOI: 10.1128/Aac.45.3.743-748.2001 |
0.556 |
|
2000 |
Mangel WF, Toledo DL, Brown MT, Ding J, Sweet RM, Barnard DL, McGrath WJ. Adenovirus Proteinase-Antiviral Target for Triple-Combination Therapy on a Single Enzyme: Potential Inhibitor-Binding Sites Handbook of Experimental Pharmacology. 140: 145-158. DOI: 10.1007/978-3-642-57092-6_8 |
0.482 |
|
1999 |
Barnard DL, Sidwell RW, Xiao W, Player MR, Adah SA, Torrence PF. 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection. Antiviral Research. 41: 119-34. PMID 10320045 DOI: 10.1016/S0166-3542(99)00005-4 |
0.4 |
|
1999 |
Lin YM, Flavin MT, Schure R, Chen FC, Sidwell R, Barnard DL, Huffman JH, Kern ER. Antiviral activities of biflavonoids. Planta Medica. 65: 120-5. PMID 10193201 DOI: 10.1055/s-1999-13971 |
0.377 |
|
1998 |
Player MR, Barnard DL, Torrence PF. Potent inhibition of respiratory syncytial virus replication using a 2-5A-antisense chimera targeted to signals within the virus genomic RNA. Proceedings of the National Academy of Sciences of the United States of America. 95: 8874-9. PMID 9671772 DOI: 10.1073/Pnas.95.15.8874 |
0.399 |
|
1998 |
Sidwell RW, Huffman JH, Barnard DL, Bailey KW, Wong MH, Morrison A, Syndergaard T, Kim CU. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Research. 37: 107-20. PMID 9588843 DOI: 10.1016/S0166-3542(97)00065-X |
0.56 |
|
1997 |
Barnard DL, Hill CL, Gage T, Matheson JE, Huffman JH, Sidwell RW, Otto MI, Schinazi RF. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes Antiviral Research. 34: 27-37. PMID 9107383 DOI: 10.1016/S0166-3542(96)01019-4 |
0.521 |
|
1997 |
Barnard DL, Bischofberger N, Kim CU, Huffman JH, Sidwell RW, Dougherty JP, Lew W, Williams MA, Yang W. Acyclic Phosphonomethylether Nucleoside Inhibitors of Respiratory Viruses Antiviral Chemistry & Chemotherapy. 8: 223-233. DOI: 10.1177/095632029700800306 |
0.487 |
|
1997 |
Huffman J, Sidwell R, Barnard D, Morrison A, Otto M, Hill C, Schinazi R. Influenza Virus-Inhibitory Effects of a Series of Germanium- and Silicon-Centred Polyoxometalates Antiviral Chemistry and Chemotherapy. 8: 75-83. DOI: 10.1177/095632029700800201 |
0.446 |
|
1995 |
Barnard DL, Fairbairn DW, O'Neill KL, Gage TL, Sidwell RW. Anti-human cytomegalovirus activity and toxicity of sulfonated anthraquinones and anthraquinone derivatives. Antiviral Research. 28: 317-29. PMID 8669891 DOI: 10.1016/0166-3542(95)00057-7 |
0.368 |
|
1995 |
Sidwell RW, Huffman JH, Barnard DL, Smee DF, Warren RP, Chirigos MA, Kende M, Huggins J. Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections. Antiviral Research. 25: 105-22. PMID 7847873 DOI: 10.1016/0166-3542(94)90100-7 |
0.554 |
|
1995 |
Barnard D, Hill C, Gage T, Sidwell R, Schinazi R. Anti-respiratory syncytial virus activity of selected polyoxometalates Antiviral Research. 26: A349. DOI: 10.1016/0166-3542(95)94934-T |
0.485 |
|
1994 |
Ubillas R, Jolad SD, Bruening RC, Kernan MR, King SR, Sesin DF, Barrett M, Stoddart CA, Flaster T, Kuo J, Ayala F, Meza E, Castañel M, McMeekin D, Rozhon E, ... ... Barnard D, et al. SP-303, an antiviral oligomeric proanthocyanidin from the latex of Croton lechleri (Sangre de Drago). Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 1: 77-106. PMID 23195881 DOI: 10.1016/S0944-7113(11)80026-7 |
0.51 |
|
1994 |
Barnard DL, Huffman JH, Sidwell RW, Reist EJ. Selective inhibition of cytomegaloviruses by 9-(3'-ethylphosphono-1'-hydroxymethyl-1'-propyloxy-methyl)g uanine. Antiviral Research. 22: 77-89. PMID 8250544 DOI: 10.1016/0166-3542(93)90086-X |
0.475 |
|
1993 |
Barnard DL, Huffman JH, Meyerson LR, Sidwell RW. Mode of inhibition of respiratory syncytial virus by a plant flavonoid, SP-303. Chemotherapy. 39: 212-7. PMID 8508691 DOI: 10.1159/000239128 |
0.433 |
|
1993 |
Barnard DL, Smee DF, Huffman JH, Meyerson LR, Sidwell RW. Antiherpesvirus activity and mode of action of SP-303, a novel plant flavonoid. Chemotherapy. 39: 203-11. PMID 7685261 DOI: 10.1159/000239127 |
0.428 |
|
1992 |
Smee DF, Morris JL, Barnard DL, Van Aerschot A. Selective inhibition of arthropod-borne and arenaviruses in vitro by 3'-fluoro-3'-deoxyadenosine. Antiviral Research. 18: 151-62. PMID 1365816 DOI: 10.1016/0166-3542(92)90035-4 |
0.469 |
|
1992 |
Barnard DL, Huffman JH, Morris JL, Wood SG, Hughes BG, Sidwell RW. Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus. Antiviral Research. 17: 63-77. PMID 1310583 DOI: 10.1016/0166-3542(92)90091-I |
0.344 |
|
1991 |
Barnard D, Huffman J, Wood S. Characterization of the anti-human Cytomegalovirus (HCMV) activity of three anthraquinone compounds Antiviral Research. 15: 99. DOI: 10.1016/0166-3542(91)90189-X |
0.331 |
|
1989 |
Sidwell RW, Huffman JH, Barnard DL, Pifat DY. Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections. Antiviral Research. 10: 193-207. PMID 2976263 DOI: 10.1016/0166-3542(88)90031-9 |
0.476 |
|
1989 |
Sidwell R, Huffman J, Barnard D, Reist E. EFFECT OF PHOSPHONIC ACID ANALOGS OF ACYCLOVIR AND GANCICLOVIR ON IN VITRO CYTOMEGALOVIRUS INFECTIONS Nucleosides, Nucleotides and Nucleic Acids. 8: 833-836. DOI: 10.1080/07328318908054224 |
0.45 |
|
Show low-probability matches. |